Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Zinecard, Totect. Every FDA application for this active ingredient: 2 branded and 4 generic.
As of Nov 15, 2026, FDA lists 6 applications for Dexrazoxane Hydrochloride (sold as Zinecard, Totect), first approved May 26, 1995, with 2 new uses approved and 0 published complete response letters.
First approved: May 26, 1995
Applications: 6
New uses approved: 2
Complete response letters: 0
Medicare spending, 2025: $552K
First approved in the EU: Jul 27, 2006
First approved in Japan: Jan 17, 2014
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 224 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Savene Injectable, new ingredientA drug with a new active ingredient indicated for the treatment of anthracycline extravasation. · Kissei Pharmaceutical Co., Ltd. · Jan 17, 2014
Clinical Trials
18 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
The CARDIOPROTECT TrialDiffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity · Beth Israel Deaconess Medical Center
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Pfizer
Hikma
Eugia Pharma